Navigation Links
FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
Date:8/30/2007

SUNNYVALE, Calif., Aug. 30 /PRNewswire/ -- Conformia, one of the FDA's Cooperative Research and Development Agreement (CRADA) Partners, joined forces with the Food and Drug Administration (FDA) on August 23, 2007, in a presentation focusing on the FDA's Quality by Design (QbD) initiative at the Third Annual Regulatory and Compliance Symposium -- "Managing Risks -- From Pipeline to Patient." The symposium was held at Harvard University.

Helen Winkle, Director of the Office of Pharmaceutical Sciences, a part of the Center for Drug Evaluation and Research, shared the progress the FDA is making, as well as the challenges that both the FDA and the industry face in moving to the "desired state." Winkle pointed out that Chemistry Manufacturing and Controls (CMC) requirements are part of the critical path both within the FDA and within industry, and described how the Quality by Design (QbD) initiative is created to help reduce excessive regulatory burden and provide mechanisms for regulatory flexibility.

Anjali Kataria, principal investigator of the FDA-Conformia Cooperative Research and Development Agreement (CRADA) study, presented research from the CRADA study of nine blinded pharmaceutical / biotech companies. She highlighted results including the bottlenecks and obstacles companies face in implementing QbD, as well as the top priorities study companies articulated -- such as gaining more assurance from the FDA that reviewers, inspectors and policy makers are all being trained to support the "desired state."

Winkle and Kataria presented both findings and actions resulting from part one of the Conformia CRADA study that queried pharmaceutical and biotech leaders about meeting the goals of the FDA's QbD initiative. The preliminary findings led to an expanded CRADA study and a series of first-of-a-kind Conformia-FDA-PhRMA trainings for cross-functional pharmaceutical leadership teams.

The Harvard presentation focused on:

-- The state of pharmaceutical manufacturing

-- Consequences pharmaceutical companies face in the present environment

-- The current state of the regulatory quality review process

-- The mutual goal for industry, society and regulators to reliably

produce high-quality products without extensive regulatory oversight

-- Benefits of the new QbD paradigm for both the FDA and the industry

About the CRADA Study

The CRADA study began in April 2006 as a preliminary study of nine companies and is due to expand to 25 companies. Focusing on understanding the current practices of pharmaceutical development and commercialization, the study is designed to align with the FDA's Current Good Manufacturing Practice (cGMP) initiative for the 21st century and the Critical Path initiative, of which QbD is a key component. The study is unique because it enables companies to openly share their concerns with the FDA without fear of ramifications.

The presentation is available on the Conformia website -- http://www.conformia.com

About Conformia

Conformia is the market leader and innovator in product/process lifecycle management (PPLM) software solutions for regulated process industries including life sciences and beverage alcohol. These solutions enable pharmaceutical companies to save significant time and money through major improvements in product/process development operations by creating central master active pharmaceutical ingredients and formulation databases across the lifecycle. Conformia's web-based enterprise software helps improve product quality, provides a platform for regulatory flexibility, decreases time to market, increases product / process operational effectiveness and streamlines tech transfer. Conformia is offered as an SAP-endorsed business solution for pharmaceutical development operations and beverage alcohol operations. Together SAP and Conformia are building a bridge to support the product/process lifecycle from development to manufacturing thereby enabling companies to achieve Quality by Design across the lifecycle. For more information, go to http://www.conformia.com.

Conformia is a registered trademark of Conformia Software Inc. All other brands, products, or service names are or may be trademarks or service marks of their respective owners.


'/>"/>
SOURCE Conformia
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. pFB-ERV: Retroviral Delivery of the Ecdysone Receptor Proteins
2. High-Titer Retroviral Vectors for Gene Delivery
3. Unique Enhanced DNA Polymerase Delivers High Fidelity and Great PCR Performance
4. Effectene Transfection Reagent provides efficient gene delivery to primary neuronal cell cultures
5. A New Way to Assess siRNA Delivery Efficiency
6. Delivering siRNA Using Adenoviral Vectors
7. Efficient Delivery of siRNAs to Human Primary Cells: Electroporation vs. Chemical Transfection
8. Delivering siRNAs to Difficult Cell Types
9. Enhanced siRNA Delivery and Long-term Gene Silencing
10. Deliver siRNAs Into Primary Cells
11. High Throughput siRNA Delivery In Vitro: From Cell Lines to Primary Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... La Jolla, CA (PRWEB) , ... May 24, 2016 , ... ... and financial planning for corporate executives and entrepreneurs, held The Future of San Diego ... leaders in the San Diego life science community attended the event with speakers Dr. ...
(Date:5/23/2016)... , May 23, 2016 Zimmer Biomet Holdings, ... healthcare, today announced that its Board of Directors has approved ... the second quarter of 2016. The cash ... about July 29, 2016 to stockholders of record as of ... of dividends are subject to approval of the Board of ...
(Date:5/23/2016)... ... May 23, 2016 , ... Foresight Institute , ... the winners for the 2015 Foresight Institute Feynman Prizes. , These prestigious ... categories, one for experiment and the other for theory in nanotechnology. Prof. Markus ...
(Date:5/20/2016)... ... , ... Korean researchers say Manumycin A triggers apoptosis, or natural cell death, ... the disease. Surviving Mesothelioma has just posted an article on the new study. ... their mesothelioma study on the fact the Manumycin A, a derivative of Streptomyces parvulus, ...
Breaking Biology Technology:
(Date:3/18/2016)... --> --> Competitive Landscape ... Vehicles, Physical infrastructure and Perimeter Surveillance & Detection Systems ... market and the continuing migration crisis in the ... has led visiongain to publish this unique report, which is ... & security companies in the border security market and ...
(Date:3/15/2016)... , March 15, 2016 Yissum Research ... the technology-transfer company of the Hebrew University, announced today ... remote sensing technology of various human biological indicators. Neteera ... $2.0 million from private investors. ... on the detection of electromagnetic emissions from sweat ducts, ...
(Date:3/11/2016)... March 11, 2016 http://www.apimages.com ) - ... Picture is available at AP Images ( http://www.apimages.com ) - ... be used to produce the new refugee identity cards. DERMALOG will ... at CeBIT in Hanover next week.   ... will be used to produce the new refugee identity cards. DERMALOG ...
Breaking Biology News(10 mins):